Wire · opportunities
At-Home Lecanemab: What Does It Mean for Alzheimer's Care?
◆ Sectors
Health
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 28 August 2026 · Fusion42 review
The FDA has approved at-home subcutaneous dosing of lecanemab for patients with mild cognitive impairment or mild Alzheimer's dementia, moving antiamyloid therapy from infusion centres into patients' homes while maintaining crucial MRI monitoring and clinician oversight.
This Wire brief sits within Fusion42's coverage of Health.
◆ ◆ The Wire takeaway
You now need to prepare for guiding patients through home lecanemab use with training and oversight, making patient selection and ongoing monitoring your new frontline challenges in managing early Alzheimer's treatment.
◆ Coverage
1 source · 28 Aug 2026
◆ Related on Wire
◆ Topics
Healthalzheimersfda-approvalhome-carelecanemabsubcutaneous-dosing